What is Rallybio?
Rallybio is a biotechnology company dedicated to identifying and accelerating the development of novel therapies for patients suffering from severe and rare diseases. Established in January 2018, the company has strategically built a portfolio of promising product candidates targeting unmet needs in hematology, immuno-inflammation, and metabolism. Rallybio's focus on rare disorders positions it within a critical segment of the pharmaceutical market, aiming to deliver significant therapeutic advancements where options are often limited.
How much funding has Rallybio raised?
Rallybio has raised a total of $355.8M across 4 funding rounds:
Series A
$37M
Share Placement
$93.2M
Series B
$145M
Share Placement
$80.6M
Series A (2018): $37M, investors not publicly disclosed
Share Placement (2020): $93.2M, investors not publicly disclosed
Series B (2020): $145M supported by Solasta Ventures, Tekla Life Sciences Investors, VIKING GLOBAL INVESTORS L.P., PIVOTAL BIOVENTURE PARTNERS LLC, Mitsui & Co., F-Prime Capital, Fairview Capital Partners Inc, and The Rise Fund
Share Placement (2021): $80.6M, investors not publicly disclosed
Key Investors in Rallybio
Mitsui & Co.
Mitsui & Co. is a global trading and investment company operating in more than 60 countries with a diverse portfolio spanning multiple industries. The company develops and grows its businesses in collaboration with a worldwide network of trusted partners, leveraging its geographic reach and cross-industry expertise to create long-term sustainable value for stakeholders. Mitsui’s current Medium-term Management Plan focuses on three strategic initiatives: supporting industry growth through stable supplies of resources and infrastructure, promoting the global transition to low-carbon and renewable energy, and enhancing quality of life by delivering healthcare solutions and access to good nutrition.
F-Prime Capital
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies. F-Prime Capital is located in Massachusetts.
The Rise Fund
The Rise Fund, founded in 2016, is an impact investing platform that focuses on investing in growth-stage, mission-driven companies aligned with the United Nations' Sustainable Development Goals. The fund specializes in multiple sectors including climate and conservation, education, food and agriculture, financial inclusion, healthcare, and impact services. Based in North America, The Rise Fund operates as part of the TPG Rise platform, working to achieve positive social and environmental outcomes while generating competitive financial returns. The fund invests in companies across various countries and provides expertise to help these organizations scale their impact-focused operations.
What's next for Rallybio?
The recent major strategic investment provides Rallybio with significant resources to advance its clinical-stage product candidates. This infusion of capital is expected to fuel further development, potentially enabling the company to progress through key clinical trial milestones and expand its research and development capabilities. Rallybio's strategic approach to addressing rare diseases, coupled with this latest backing, suggests a trajectory focused on achieving regulatory approvals and bringing much-needed treatments to market, thereby solidifying its position in the competitive biotech landscape.
See full Rallybio company page
